ReviewNanomedicine (London, England)2013
Current trends in the use of liposomes for tumor targeting.
Review in Nanomedicine (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 216 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
216 citing papers in PubMed.
- Rapid Fc-mediated surface modification of liposomes with antibodies for selective targeting of pancreatic tumors.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Stepwise effects of formulation additives and process parameters on ethanol injection-prepared nanoliposomes for cancer delivery: a preformulation study.Scientific reports · 2026Article
- Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.Communications medicine · 2026Article
- Plant Lipid Droplets and Derived Lipidic Nano-Assemblies: Structure, Biogenesis and Pharmaceutical Applications.Plant biotechnology journal · 2026Review
- Nature Inspired Delivery Vehicles for CRISPR-Based Genome Editing.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Synergistic combinatorial anticancer potential of Tamoxifen with Naringin and Diosmetin in MCF-7 breast cancer cells and their liposomal delivery.Scientific reports · 2026Article
- The Potential of Next-generation Multi-functional Nanoplatforms for Breast Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Review
- A Complete Sojourn of Liposomes in Breast Cancer Therapy: Types, Preparation Techniques, Lipid Selection, and Critical Quality Attributes.Current drug research reviews · 2026Review
- Next-generation nanomedicine for cancer therapy: advances, challenges, and future perspectives.Frontiers in chemistry · 2026Review
- Recent Developments in Vesicular Nanocarriers for Targeted Drug Delivery in Breast Cancer.Current pharmaceutical design · 2026Review
- Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer.ACS nano · 2025Article
- Advancing cancer radiotherapy: Harnessing radiosensitizers and nanotechnology for enhanced tumor control.International journal of pharmaceutics: X · 2025Review
- AI-guided design of a CXCR4-targeted core-shell nanocarrier for co-delivery of berberine/paclitaxel in cancer therapy.Journal of nanobiotechnology · 2025Article
- Preparation of liposomal nanocarriers containing all-trans retinoic acid and docetaxel and their evaluation in a lung cancer cell line.Scientific reports · 2025Article
- Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.Research square · 2025Article
- Sodium alginate-hyaluronic acid composite particles for doxorubicin delivery: in vitro characterization and cytotoxicity evaluation.BMC research notes · 2025Article
- Liposomal Formulations for Efficient Delivery of a Novel, Highly Potent Pyrimidine-Based Anticancer Drug.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Medulloblastoma: Molecular Targets and Innovative Theranostic Approaches.Pharmaceutics · 2025Review
- Submicron-sized superantigen biomimetic liposomes with highly efficient pulmonary accumulation to remodel local immune microenvironment for cancer chemoimmunotherapy.Acta pharmaceutica Sinica. B · 2025Article
156 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The use of liposomes for drug delivery began early in the history of pharmaceutical nanocarriers. These nanosized, lipid bilayered vesicles have become popular as drug delivery systems owing to their efficiency, biocompatibility, nonimmunogenicity, enhanced solubility of chemotherapeutic agents and their ability to encapsulate a wide array of drugs. Passive and ligand-mediated active targeting promote tumor specificity with diminished adverse off-target effects. The current field of liposomes focuses on both clinical and diagnostic applications. Recent efforts have concentrated on the development of multifunctional liposomes that target cells and cellular organelles with a single delivery system. This review discusses the recent advances in liposome research in tumor targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.